GlassScriptPhysician profile
Eric D Mininberg
NPI 1275591067
$1,889.48
in general payments reported to CMS, 2019-2025
41 companies · $289 in 2025
The $289 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $183 · 2020: $188 · 2021: $234 · 2022: $328 · 2023: $418 · 2024: $250 · 2025: $289.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $920 · Education: $36.83.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $920.25 |
| Education | $36.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $360.46 | 2021-2025 | |
| Intera Oncology, INC | $152.62 | 2023 | Intera 3000 Implantable Pump |
| Pharmacyclics LLC, An Abbvie Company | $148.44 | 2021-2023 | Imbruvica |
| Mentor Worldwide LLC | $142.85 | 2022 | |
| Seagen INC. | $101.07 | 2020-2021 | |
| Janssen Biotech, INC. | $76.62 | 2019-2025 | Rybrevant |
| Pfizer INC. | $72.59 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $47.18 | 2019 | |
| Epizyme, INC. | $46.79 | 2021-2023 | Tazverik |
| Daiichi Sankyo INC. | $45.48 | 2021-2025 | Enhertu |
| Astellas Pharma US INC | $44.45 | 2020 | |
| Janssen Pharmaceuticals, INC | $41.85 | 2022-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $39.52 | 2019-2023 | Keytruda |
| Genzyme Corporation | $38.72 | 2020-2025 | |
| Amgen INC. | $37.34 | 2022 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Mininberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.